Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
A medicine that is FDA-approved for bone marrow stimulation (called sargramostim) will be
tested for its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease
over a six month treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Alzheimer's Association National Institute on Aging (NIA) Partner Therapeutics Partner Therapeutics, Inc.